Dataset Information

Analysis of network disruption evolution of Chinese fresh cold chain under COVID-19.

ABSTRACT: The spread of the global COVID-19 epidemic, home quarantine, and blockade of infected areas are essential measures to prevent the spread of the epidemic, but efforts to prevent and control the outbreak lead to the disruption of fresh and cold chain agricultural products in the region. Based on the multi-layer management model of non-scale agricultural households in China, we applied the complex network theory to construct an evolutionary model of the Chinese fresh cold chain network with adaptation degree priority connection, dual local world considering transport distance connection relationship, and superiority and inferiority mechanism. Based on this model, we studied the evolution of fresh cold chain disruption, and puts forward the optimal design of fresh cold chain network disruption and reconnection from the perspective of practicality and economy.

SUBMITTER: Chen H

PROVIDER: S-EPMC9879514 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Analysis of network disruption evolution of Chinese fresh cold chain under COVID-19.

Chen Huanwan H Chen Guopeng G Zhang Qingnian Q Zhang Xiuxia X

PloS one 20230126 1

The spread of the global COVID-19 epidemic, home quarantine, and blockade of infected areas are essential measures to prevent the spread of the epidemic, but efforts to prevent and control the outbreak lead to the disruption of fresh and cold chain agricultural products in the region. Based on the multi-layer management model of non-scale agricultural households in China, we applied the complex network theory to construct an evolutionary model of the Chinese fresh cold chain network with adaptat ...[more]

PMID: 36701281

Similar Datasets

Project description:Study questionDoes prior severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in women undergoing fertility treatments affect the outcomes of fresh ART cycles?Summary answerSARS-CoV-2 infection does not affect fresh ART treatment outcomes, except for a possible long-term negative effect on oocyte yield (>180 days postinfection).What is known alreadyA single previous study suggested no evidence that a history of asymptomatic or mild SARS-CoV-2 infection in females caused impairment of fresh ART treatment outcomes.Study design, size, durationRetrospective cohort study, including all SARS-CoV-2 infected women who underwent fresh ART cycles within a year from infection (the first cycle postinfection), between October 2020 and June 2021, matched to non-diagnosed controls.Participants/materials, setting, methodsPatients from two large IVF units in Israel who were infected with SARS-CoV-2 and later underwent fresh ART cycles were matched by age to non-diagnosed, non-vaccinated controls. Demographics, cycle characteristics and cycle outcomes, including oocyte yield, maturation rate, fertilization rate, number of frozen embryos per cycle and clinical pregnancy rates, were compared between groups.Main results and the role of chanceOne hundred and twenty-one infected patients and 121 controls who underwent fresh ART cycles were included. Oocyte yield (12.50 versus 11.29; P = 0.169) and mature oocyte rate (78% versus 82%; P = 0.144) in all fresh cycles were similar between groups, as were fertilization rates, number of frozen embryos per cycle and clinical pregnancy rates (43% versus 40%; P = 0.737) in fresh cycles with an embryo transfer. In a logistic regression model, SARS-CoV-2 infection more than 180 days prior to retrieval had a negative effect on oocyte yield (P = 0.018, Slope = -4.08, 95% CI -7.41 to -0.75), although the sample size was small.Limitations, reasons for cautionA retrospective study with data that was not uniformly generated under a study protocol, no antibody testing for the control group.Wider implications of the findingsThe study findings suggest that SARS-CoV-2 infection does not affect treatment outcomes, including oocyte yield, fertilization and maturation rate, number of good quality embryos and clinical pregnancy rates, in fresh ART cycles, except for a possible long-term negative effect on oocyte yield when retrieval occurs >180 days post-SARS-CoV-2 infection. Further studies are warranted to support these findings.Study funding/competing interest(s)None.Trial registration number0010-21-HMC, 0094-21-ASF.

Project description:BackgroundSuccessful mass vaccination programmes are public health achievements of the contemporary world. While pharmaceutical companies are actively developing new vaccines, and demonstrating results of effectiveness and safety profiles, concerns on COVID-19 vaccine management are under-reported. We aimed to synthesise the evidence for efficient cold chain management of COVID vaccines.MethodsThe scoping review's conduct and reporting were based on the PRISMA-ScR 2018 checklist. We searched from April 2020 to January 2022 for publications in PubMed (LitCovid), Scopus and ScienceDirect. All review stages were pilot-tested to calibrate 2 reviewers. Articles on cold chain logistics and management were included, while publications solely describing COVID vaccines, their development and clinical aspects of the vaccine, were excluded. To capture relevant data, charting was conducted by one reviewer and verified by another. Results were analysed thematically and summarised descriptively in a table and in-text.Results and discussionWe assessed 6984 potentially relevant citations. We included 14 publications originating from USA (n = 6), India (n = 2), Finland, Spain, Bangladesh, Netherlands, Switzerland and Ethiopia. They were reported as reviews (4), policy or guidance documents (3), experimental studies (2), case reports (2), expert commentary (1), phenomenological study (1), and decision-making trial and evaluation laboratory trial (1). The findings were presented in three themes: (i) regulatory requirements for cold-chain logistics, (ii) packaging and storage, and (iii) transportation and distribution. A conceptual framework emerged linking regulatory requirements, optimal logistics operation and formulation stability as the key to efficient cold chain management. Recommendations were made for improving formulation stability, end-product storage conditions, and incorporating monitoring technologies.ConclusionCOVID-19 vaccines require special end-to-end supply cold chain requirements, from manufacture, and transportation to warehouses and healthcare facilities. To sustain production, minimise wastage, and for vaccines to reach target populations, an efficient and resilient vaccine supply chain which is assisted by temperature monitoring technologies is imperative.

Dataset Information

Analysis of network disruption evolution of Chinese fresh cold chain under COVID-19.

Publications

Analysis of network disruption evolution of Chinese fresh cold chain under COVID-19.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets